FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

More Support for Treating All Biologics the Same

[ Price : $8.95]

Two drug trade associations support an FDA approach to postapproval manufacturing changes in biosimilar and interchangeable biosim...

FDA OKs AZs Tagrisso Lung Cancer Drug

[ Price : $8.95]

FDA approves AstraZenecas Tagrisso for some non-small cell lung cancers.

Lilly Sues FDA Over Retatrutide Designation

[ Price : $8.95]

Lilly asks an Indiana federal court to overturn an FDA determination that the companys retatrutide is a drug rather than a biologi...

Azurity Selling Unapproved Drugs: FDA

[ Price : $8.95]

FDA warns Wilmington, MA-based Azurity Pharmaceuticals it is manufacturing and marketing unapproved new drugs with CGMP violations...

Regulatory Review Period for Quviviq

[ Price : $8.95]

Federal Register notice: FDA determines for patent extension purposes the regulatory review period for Idorsia Pharmaceuticals Quv...

ODAC Discussing Immune Checkpoint Inhibitors

[ Price : $8.95]

FDA issues two briefing documents to facilitate discussion by the Oncology Drugs Advisory Committee of the risk/benefit assessment...

Regulatory Review Period for Ojjaara

[ Price : $8.95]

Federal Register notice: FDA determines for patent extension purposes the regulatory review period for GlaxoSmithKlines Ojjaara (m...

Treat all Biologics the Same: Stakeholders

[ Price : $8.95]

Two stakeholders say it is important that FDA state that principles in a question-and-answer guidance on pre-approval manufacturin...

House Passes Pediatric/Rare Disease Bill

[ Price : $8.95]

The U.S. House of Representatives passes the Give Kids a Chance Act (HR 3433) that is intended to address childhood cancer and rar...

Eisai Facility FDA-483 Out

[ Price : $8.95]

FDA releases the form FDA-483 issued following a 2023 inspection at an Eisai drug manufacturing facility in Gifu, Japan.